<img alt="" height="1" width="1" />Ironwood Pharmaceuticals Announces Upcoming Presentation at Morgan Stanley ...MarketWatch (press release)Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation ...<nobr>and more »</nobr> |